Shots:
- Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use
- Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug delivery
- AmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force for easy delivery via conventional syringe, which rapidly forms a drug depot upon warming to body temperature
Ref: Prnewswire | Image: Merck Animal Health & AmacaThera
Related News:- Merck Animal Health Receives the EC’s Approval of BRAVECTO TriUNO for Use in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
